Publications
Filters: First Letter Of Keyword is H [Clear All Filters]
Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group." Stat Med 34, no. 14 (2015): 2181-95.
"Responses to discussants of 'Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group'." Stat Med 34, no. 14 (2015): 2202-3.
"Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group." Stat Med 34, no. 14 (2015): 2181-95.
"Bayesian lasso for semiparametric structural equation models." Biometrics 68, no. 2 (2012): 567-77.
"Optimal two-stage dynamic treatment regimes from a classification perspective with censored survival data." Biometrics 74, no. 4 (2018): 1180-1192.
"Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial." J Clin Oncol 37, no. 8 (2019): 624-635.
"Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Future Oncol 12, no. 11 (2016): 1359-67.
"A general framework for association tests with multivariate traits in large-scale genomics studies." Genet Epidemiol 37, no. 8 (2013): 759-67.
"Sparse meta-analysis with high-dimensional data." Biostatistics 17, no. 2 (2016): 205-20.
"Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates." Bioinformatics 32, no. 1 (2016): 50-7.
"Biclustering via sparse clustering." Biometrics 76, no. 1 (2020): 348-358.
"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
"Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS." Eur Heart J Acute Cardiovasc Care 2, no. 3 (2013): 246-55.
"LIBERTI: A SMART study in plastic surgery." Clin Trials 15, no. 3 (2018): 286-293.
"A general framework for studying genetic effects and gene-environment interactions with missing data." Biostatistics 11, no. 4 (2010): 583-98.
"Meta-analysis of gene-level associations for rare variants based on single-variant statistics." Am J Hum Genet 93, no. 2 (2013): 236-48.
"A general framework for studying genetic effects and gene-environment interactions with missing data." Biostatistics 11, no. 4 (2010): 583-98.
"Sample size/power calculation for stratified case-cohort design." Stat Med 33, no. 23 (2014): 3973-85.
"Analysis of untyped SNPs: maximum likelihood and imputation methods." Genet Epidemiol 34, no. 8 (2010): 803-15.
"Integrative analysis of sequencing and array genotype data for discovering disease associations with rare mutations." Proc Natl Acad Sci U S A 112, no. 4 (2015): 1019-24.
"Analysis of untyped SNPs: maximum likelihood and imputation methods." Genet Epidemiol 34, no. 8 (2010): 803-15.
"Integrative gene set analysis of multi-platform data with sample heterogeneity." Bioinformatics 30, no. 11 (2014): 1501-7.
"Semiparametric Bayesian local functional models for diffusion tensor tract statistics." Neuroimage 63, no. 1 (2012): 460-74.
"Diseased Region Detection of Longitudinal Knee Magnetic Resonance Imaging Data." IEEE Trans Med Imaging 34, no. 9 (2015): 1914-27.
"Characterizing expected benefits of biomarkers in treatment selection." Biostatistics 16, no. 2 (2015): 383-99.
"The Long Noncoding RNA Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways." Mol Cancer Res 18, no. 10 (2020): 1534-1544.
"Diseased region detection of longitudinal knee MRI data." Inf Process Med Imaging 23 (2013): 632-43.
"Detection of gene-gene interactions using multistage sparse and low-rank regression." Biometrics 72, no. 1 (2016): 85-94.
"Spatial regression with covariate measurement error: A semiparametric approach." Biometrics 72, no. 3 (2016): 678-86.
"SGPP: spatial Gaussian predictive process models for neuroimaging data." Neuroimage 89 (2014): 70-80.
"Bayesian probability of success for clinical trials using historical data." Stat Med 34, no. 2 (2015): 249-64.
"The power prior: theory and applications." Stat Med 34, no. 28 (2015): 3724-49.
"Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes." Biometrics 68, no. 2 (2012): 578-86.
"Bayesian probability of success for clinical trials using historical data." Stat Med 34, no. 2 (2015): 249-64.
"Bayesian multivariate skew meta-regression models for individual patient data." Stat Methods Med Res 28, no. 10-11 (2019): 3415-3436.
"Missing data in clinical studies: issues and methods." J Clin Oncol 30, no. 26 (2012): 3297-303.
"Basic concepts and methods for joint models of longitudinal and survival data." J Clin Oncol 28, no. 16 (2010): 2796-801.
"Bayesian probability of success for clinical trials using historical data." Stat Med 34, no. 2 (2015): 249-64.
"Bayesian multivariate skew meta-regression models for individual patient data." Stat Methods Med Res 28, no. 10-11 (2019): 3415-3436.
"Fixed and random effects selection in mixed effects models." Biometrics 67, no. 2 (2011): 495-503.
"Bayesian probability of success for clinical trials using historical data." Stat Med 34, no. 2 (2015): 249-64.
"Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690." BMC Med Res Methodol 12 (2012): 183.
"Bayesian multivariate skew meta-regression models for individual patient data." Stat Methods Med Res 28, no. 10-11 (2019): 3415-3436.
"Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes." Biometrics 68, no. 2 (2012): 578-86.
"Genetic variation determines VEGF-A plasma levels in cancer patients." Sci Rep 8, no. 1 (2018): 16332.
"Nine-year change in statistical design, profile, and success rates of Phase II oncology trials." J Biopharm Stat 26, no. 1 (2016): 141-9.
"The rapid enrollment design for Phase I clinical trials." Stat Med 35, no. 15 (2016): 2516-24.
"Effective SNP ranking improves the performance of eQTL mapping." Genet Epidemiol 44, no. 6 (2020): 611-619.
"Rare Variants Association Analysis in Large-Scale Sequencing Studies at the Single Locus Level." PLoS Comput Biol 12, no. 6 (2016): e1004993.
"Rare Variants Association Analysis in Large-Scale Sequencing Studies at the Single Locus Level." PLoS Comput Biol 12, no. 6 (2016): e1004993.
"Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity." Pharmacogenomics 14, no. 2 (2013): 205-13.
"Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity." Pharmacogenomics 14, no. 2 (2013): 205-13.
"Selection of the initial design for the two-stage continual reassessment method." J Biopharm Stat 27, no. 3 (2017): 495-506.
"Precision Medicine Approach to Develop and Internally Validate Optimal Exercise and Weight-Loss Treatments for Overweight and Obese Adults With Knee Osteoarthritis: Data From a Single-Center Randomized Trial." Arthritis Care Res (Hoboken) 73, no. 5 (2021): 693-701.
"Incorporating Functional Information in Tests of Excess De Novo Mutational Load." Am J Hum Genet 97, no. 2 (2015): 272-83.
"CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing." Genome Biol 19, no. 1 (2018): 202.
"Incorporating Functional Information in Tests of Excess De Novo Mutational Load." Am J Hum Genet 97, no. 2 (2015): 272-83.
"CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing." Genome Biol 19, no. 1 (2018): 202.
"Proportional exponentiated link transformed hazards (ELTH) models for discrete time survival data with application." Lifetime Data Anal 22, no. 1 (2016): 38-62.
"Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker." J Biopharm Stat 29, no. 4 (2019): 685-695.
"Phase II cancer clinical trials with heterogeneous patient populations." J Biopharm Stat 22, no. 2 (2012): 312-28.
"K-Sample comparisons using propensity analysis." Biom J 61, no. 3 (2019): 698-713.
"Statistical Methods for Conditional Survival Analysis." J Biopharm Stat 28, no. 5 (2018): 927-938.
"Randomized phase II clinical trials." J Biopharm Stat 24, no. 4 (2014): 802-16.
"Power and sample size calculation for microarray studies." J Biopharm Stat 22, no. 1 (2012): 30-42.
"Phase II cancer clinical trials for biomarker-guided treatments." J Biopharm Stat 28, no. 2 (2018): 256-263.
"On sample size calculation for comparing survival curves under general hypothesis testing." J Biopharm Stat 22, no. 3 (2012): 485-95.
"Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials." Contemp Clin Trials 42 (2015): 9-17.
"Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma." Cancer Discov 7, no. 10 (2017): 1116-1135.
"Efficient estimation for accelerated failure time model under case-cohort and nested case-control sampling." Biometrics 73, no. 1 (2017): 114-123.
"Kappa statistic for clustered dichotomous responses from physicians and patients." Stat Med 32, no. 21 (2013): 3700-19.
"Marginal additive hazards model for case-cohort studies with multiple disease outcomes: an application to the Atherosclerosis Risk in Communities (ARIC) study." Biostatistics 14, no. 1 (2013): 28-41.
"Subgroup detection and sample size calculation with proportional hazards regression for survival data." Stat Med 36, no. 29 (2017): 4646-4659.
"Efficient estimation for accelerated failure time model under case-cohort and nested case-control sampling." Biometrics 73, no. 1 (2017): 114-123.
"Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART." Contemp Clin Trials 57 (2017): 51-57.
"Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs." Stat Med 32, no. 23 (2013): 3972-90.
"Analysis of multiple survival events in generalized case-cohort designs." Biometrics 74, no. 4 (2018): 1250-1260.
"Prediction of a time-to-event trait using genome wide SNP data." BMC Bioinformatics 14 (2013): 58.
"Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs." Stat Med 32, no. 23 (2013): 3972-90.
"Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs." Stat Med 32, no. 23 (2013): 3972-90.
"Improving the efficiency of estimation in the additive hazards model for stratified case-cohort design with multiple diseases." Stat Med 35, no. 2 (2016): 282-93.
"Statistical significance for hierarchical clustering." Biometrics 73, no. 3 (2017): 811-821.
"Common variants in psychiatric risk genes predict brain structure at birth." Cereb Cortex 24, no. 5 (2014): 1230-46.
"Impact of sex and gonadal steroids on neonatal brain structure." Cereb Cortex 24, no. 10 (2014): 2721-31.
"Evaluating haplotype effects in case-control studies via penalized-likelihood approaches: prospective or retrospective analysis?" Genet Epidemiol 34, no. 8 (2010): 892-911.
"Evaluating haplotype effects in case-control studies via penalized-likelihood approaches: prospective or retrospective analysis?" Genet Epidemiol 34, no. 8 (2010): 892-911.
"Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data." J Alzheimers Dis 46, no. 3 (2015): 695-702.
"FLCRM: Functional linear cox regression model." Biometrics 74, no. 1 (2018): 109-117.
"Testing and estimation in marker-set association study using semiparametric quantile regression kernel machine." Biometrics 72, no. 2 (2016): 364-71.
"Predicting Alzheimer's Disease Using Combined Imaging-Whole Genome SNP Data." J Alzheimers Dis 46, no. 3 (2015): 695-702.
"Testing and estimation in marker-set association study using semiparametric quantile regression kernel machine." Biometrics 72, no. 2 (2016): 364-71.
"FLCRM: Functional linear cox regression model." Biometrics 74, no. 1 (2018): 109-117.
"Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy." Pharmacogenomics 14, no. 5 (2013): 555-74.
"Optimal estimation for regression models on τ-year survival probability." J Biopharm Stat 25, no. 3 (2015): 539-47.
"Comparison of operational characteristics for binary tests with clustered data." Stat Med 34, no. 15 (2015): 2325-33.
"Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test." Stat Med 33, no. 12 (2014): 2004-16.
"Optimal two-stage log-rank test for randomized phase II clinical trials." J Biopharm Stat 27, no. 4 (2017): 639-658.
"Dynamic treatment regimes, past, present, and future: A conversation with experts." Stat Methods Med Res 26, no. 4 (2017): 1605-1610.
"Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy." Stat Med 35, no. 8 (2016): 1245-56.
"Discussion of "Combining biomarkers to optimize patient treatment recommendation"." Biometrics 70, no. 3 (2014): 707-10.
"